In an era of health reform, diagnostic technologies that focus on prevention and test the viability of expensive treatment options are becoming increasingly valuable to health providers, payers, and patients. Historically, investment in this sector has not seen the vigor demonstrated with medical devices or biotech innovations. However, in today’s environment, diagnostics are becoming attractive opportunities for companies looking for collaborations or acquisitions as well as investors looking for cutting-edge technologies, all creating a robust industry on the brink of breaking through to the mainstream.
In this presentation, panelists will:
- Provide insight on the diagnostic industry on a local and national level
- Discuss key elements that are reviewed when assessing start-up opportunities
- Discuss where opportunities exist for maximizing profits
- Provide new strategies for raising funds in this dynamic marketplace
Panelist:
Ronald S. Eppen, Partner, Foley & Lardner LLP
Lucy Lu, Vice President of Business Development, Crescendo Bioscience
Natasha Paul, Ph.D., Scientific Investigator, TriLink Biotechnologies, Inc.
Jon Vance, Director, Avondale Partners, LLC
Related Insights
June 4, 2025
Energy Current
Nuclear’s Comeback: What Renewables Professionals Should Know
The clean energy transition isn’t a zero-sum game – it’s a team effort. And one player is stepping back into the spotlight with renewed…
June 4, 2025
Foley Ignite
M&A Disputes Set to Rise in Latin America: How Savvy Investors Are Protecting Themselves
As deal activity shows signs of rebounding in 2025, investors are bracing for an increase in M&A-related disputes globally, and Latin…
June 4, 2025
Tariff & International Trade Resource
What Every Multinational Company Should Know About … The Recent Court Decisions Striking Down the IEEPA Tariffs
This year, U.S. trade policy has undergone a dramatic shift, driven by a series of presidential proclamations that have raised tariff rates sharply.